Bruna Pellini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bruna Pellini has a total of 420 co-authors. Here are the top co-authors by number of shared publications:
- Aadel A. Chaudhuri
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
33 shared publications - Nicholas P. Semenkovich
Data Science Institute, Medical College of Wisconsin, Milwaukee, Wisconsin
26 shared publications - Cliff Grant Robinson
Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri
25 shared publications - Jyoti D. Patel
Northwestern University, Chicago, IL
25 shared publications - Saiama Naheed Waqar
Department of Medicine/Division of Oncology, Washington University School of Medicine, St. Louis, MO, United States
25 shared publications - Aaron Scott Mansfield
Mayo Clinic
24 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by MDPI AG in Preprints.org
Tumor Treating Fields Therapy After Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Single-Institution Real-World Analysis
Background/Objectives: The LUNAR trial demonstrated the benefit of Tumor Treating Fields (TTFields) therapy in patients with metastatic NSCLC (mNSCLC) after platinum-based chemotherapy. However, real-world outcomes in patients treated with contemporary systemic regimens have yet to be empirically demonstrated. Methods: In this retrospective single-institution study, patients with mNSCLC treated with TTFields (150 kHz) after platinum-based chemotherapy between 2018 and 2026 were included. Progression-free survival (PFS) and overall survival (OS) were estimated from TTFields therapy initiation using the Kaplan–Meier method. Results: Sixteen patients were included. The median age was 73 years, 63% were male, 69% had adenocarcinoma histology, and 69% were PD-L1 positive. At TTFields therapy initiation, 94% had ECOG performance status ≤ 2, 19% had brain metastases, 31% had liver metastases, and 94% had prior ICI exposure. Median PFS was 11.8 months, and median OS was 19.9 months. OS did not differ significantly between the ICI-based and docetaxel-based groups (not reached vs. 13.5 months; p = 0.60) but PFS was shorter (3.9 months vs. not reached; p = 0.046). Treatment-related dermatitis was limited to grade 1–2 events, and no grade 3 or higher device-related toxicities were observed. Conclusions: TTFields therapy demonstrated encouraging real-world OS outcomes and favorable tolerability in this first report of a contemporary post-platinum NSCLC population, supporting further prospective evaluation of optimal timing and integration with modern systemic therapies.
- 27 October 2026
- Published by MDPI AG in Preprints.org
Open AccessTumor Treating Fields Therapy After Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Single-Institution Real-World Analysis
Background/Objectives: The LUNAR trial demonstrated the benefit of Tumor Treating Fields (TTFields) therapy in patients with metastatic NSCLC (mNSCLC) after platinum-based chemotherapy. However, real-world outcomes in patients treated with contemporary systemic regimens have yet to be empirically demonstrated. Methods: In this retrospective single-institution study, patients with mNSCLC treated with TTFields (150 kHz) after platinum-based chemotherapy between 2018 and 2026 were included. Progression-free survival (PFS) and overall survival (OS) were estimated from TTFields therapy initiation using the Kaplan–Meier method. Results: Sixteen patients were included. The median age was 73 years, 63% were male, 69% had adenocarcinoma histology, and 69% were PD-L1 positive. At TTFields therapy initiation, 94% had ECOG performance status ≤ 2, 19% had brain metastases, 31% had liver metastases, and 94% had prior ICI exposure. Median PFS was 11.8 months, and median OS was 19.9 months. OS did not differ significantly between the ICI-based and docetaxel-based groups (not reached vs. 13.5 months; p = 0.60) but PFS was shorter (3.9 months vs. not reached; p = 0.046). Treatment-related dermatitis was limited to grade 1–2 events, and no grade 3 or higher device-related toxicities were observed. Conclusions: TTFields therapy demonstrated encouraging real-world OS outcomes and favorable tolerability in this first report of a contemporary post-platinum NSCLC population, supporting further prospective evaluation of optimal timing and integration with modern systemic therapies.
- Open Access
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (10)
Minority Patient–Centered Education Initiative to Increase Knowledge About Clinical Trials: A Pilot Study
Purpose: Racial and ethnic minority populations remain underrepresented in clinical trials because of restrictive eligibility criteria, systemic inequities, bias, and patient-level barriers. Educational interventions may improve awareness and participation, yet culturally tailored video–based approaches remain underused. Methods: We developed three brief culturally tailored educational videos about clinical trials in thoracic oncology for Black patients (English) and Hispanic/Latino patients (English and Spanish). Eligible patients were aged 18 years or older, had stage I to IV lung cancer, had Eastern Cooperative Oncology Group 0-2, self-identified as Black or Hispanic/Latino, and were proficient in English or Spanish. Participants completed prevideo and postvideo surveys evaluating knowledge, attitudes, and willingness to participate. Feasibility was assessed by recruitment, survey completion, and satisfaction. Acceptability, attitudes, and willingness were measured with brief surveys. Clinical trial enrollment within 1 year was also evaluated. Results: From April to September 2024, 54 patients were approached and 30 (56%) enrolled; all completed the prevideo and postvideo surveys. More than 90% reported high satisfaction. Mean knowledge scores improved ( P < .001), including understanding of preclinical studies ( P = .012), placebo use ( P = .001), and clinical trial registration ( P = .012). More than 90% agreed that clinical trials are useful and important for drug development and improved outcomes. Barriers persisted in approximately half of the participants, including concerns about consent complexity, random assignment, costs, and provider communication. Willingness to participate increased ( P = .04). Within 1 year, 17 patients (57%) had a trial available and eight (47% of eligible; 27% overall) enrolled. Conclusion: Culturally and linguistically tailored educational videos were feasible, acceptable, and associated with improved knowledge and willingness to participate. Larger studies are needed to determine whether integrating such interventions can increase minority enrollment in thoracic oncology trials.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (10)
Open AccessMinority Patient–Centered Education Initiative to Increase Knowledge About Clinical Trials: A Pilot Study
Purpose: Racial and ethnic minority populations remain underrepresented in clinical trials because of restrictive eligibility criteria, systemic inequities, bias, and patient-level barriers. Educational interventions may improve awareness and participation, yet culturally tailored video–based approaches remain underused. Methods: We developed three brief culturally tailored educational videos about clinical trials in thoracic oncology for Black patients (English) and Hispanic/Latino patients (English and Spanish). Eligible patients were aged 18 years or older, had stage I to IV lung cancer, had Eastern Cooperative Oncology Group 0-2, self-identified as Black or Hispanic/Latino, and were proficient in English or Spanish. Participants completed prevideo and postvideo surveys evaluating knowledge, attitudes, and willingness to participate. Feasibility was assessed by recruitment, survey completion, and satisfaction. Acceptability, attitudes, and willingness were measured with brief surveys. Clinical trial enrollment within 1 year was also evaluated. Results: From April to September 2024, 54 patients were approached and 30 (56%) enrolled; all completed the prevideo and postvideo surveys. More than 90% reported high satisfaction. Mean knowledge scores improved ( P < .001), including understanding of preclinical studies ( P = .012), placebo use ( P = .001), and clinical trial registration ( P = .012). More than 90% agreed that clinical trials are useful and important for drug development and improved outcomes. Barriers persisted in approximately half of the participants, including concerns about consent complexity, random assignment, costs, and provider communication. Willingness to participate increased ( P = .04). Within 1 year, 17 patients (57%) had a trial available and eight (47% of eligible; 27% overall) enrolled. Conclusion: Culturally and linguistically tailored educational videos were feasible, acceptable, and associated with improved knowledge and willingness to participate. Larger studies are needed to determine whether integrating such interventions can increase minority enrollment in thoracic oncology trials.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Bivariate Cox regression results for ctFE with respect to survival outcomes in LA-WU, adjusted for baseline covariates.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Bivariate Cox regression results for ctFE with respect to survival outcomes in LA-WU, adjusted for baseline covariates.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Pre-treatment ctDNA variant-level data per patient in LA-RW cohort.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Pre-treatment ctDNA variant-level data per patient in LA-RW cohort.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Circulating tumor fraction estimate (ctFE), molecular response, patterns of failure, and survival outcomes for all patients in the prospective LA-WU26 cohort.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Circulating tumor fraction estimate (ctFE), molecular response, patterns of failure, and survival outcomes for all patients in the prospective LA-WU26 cohort.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 12: Forest plot of multivariate cox proportional hazards regression analysis comparing the prognostic value of ctFE and Max VAF using burden-based stratification in the LA-WU cohort at pre- and mid-treatment timepoints. Hazard ratios for ctFE and Max VAF are shown as squares; horizontal bars denote 95% CIs. Low ctFE: ctFE ≤0.016411, High ctFE: ctFE >0.016411; Low Max VAF: Max VAF ≤0.0138, High Max VAF: Max VAF >0.0138. CI, confidence interval; ctFE, circulating tumor fraction estimate; HR, hazard ratio; LA-WU, locally advanced NSCLC cohort from Washington University (n = 24); Max VAF, maximum variant allele frequency; OS, overall survival; PFS, progression-free survival.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 12: Forest plot of multivariate cox proportional hazards regression analysis comparing the prognostic value of ctFE and Max VAF using burden-based stratification in the LA-WU cohort at pre- and mid-treatment timepoints. Hazard ratios for ctFE and Max VAF are shown as squares; horizontal bars denote 95% CIs. Low ctFE: ctFE ≤0.016411, High ctFE: ctFE >0.016411; Low Max VAF: Max VAF ≤0.0138, High Max VAF: Max VAF >0.0138. CI, confidence interval; ctFE, circulating tumor fraction estimate; HR, hazard ratio; LA-WU, locally advanced NSCLC cohort from Washington University (n = 24); Max VAF, maximum variant allele frequency; OS, overall survival; PFS, progression-free survival.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Purpose:Circulating tumor fraction estimate (ctFE) is a machine learning–derived composite metric of circulating tumor DNA (ctDNA) burden. We hypothesized that pre-treatment and early on-treatment ctFE could robustly risk-stratify patients with locally advanced (LA) and oligometastatic non–small cell lung cancer (NSCLC) treated with radiotherapy (RT).Experimental Design:In a prospective phase II clinical trial (NCT03916419), 26 patients with unresectable stage IIB to IIIC NSCLC received magnetic resonance (MR)-guided hypofractionated chemoradiotherapy (chemoRT) followed by immunotherapy. Plasma ctDNA was profiled at baseline and mid-treatment (days 10–14) to derive ctFE and maximum variant allele frequency (Max VAF). A burden-based ctFE threshold derived from baseline samples was applied unchanged to mid-treatment samples and validated in two external cohorts: LA NSCLC treated with chemoRT (LA-RW; n = 94) and oligometastatic NSCLC treated with RT (OM-RW; n = 309).Results:Pre- and mid-treatment ctFE burden strongly stratified overall survival (OS) and progression-free survival (PFS), outperforming Max VAF and ctFE detectability. The baseline ctFE was prognostic for OS (HR 5.93, P = 0.005) and PFS (HR 11.08, P < 0.001) and remained significant at mid-treatment (OS: HR 7.08; PFS: HR 12.06; both P < 0.001). Early ctFE dynamics defined three molecular response groups with OS separation (median OS 60.8 vs. 13.0 vs. 2.9 months; P < 0.001). ctFE remained associated with survival in both validation cohorts.Conclusions:Early ctFE derived from a clinically available, tumor-naïve ctDNA assay enables noninvasive risk stratification in LA and oligometastatic NSCLC treated with RT, supporting its use as a practical biomarker for precision treatment adaptation.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Purpose:Circulating tumor fraction estimate (ctFE) is a machine learning–derived composite metric of circulating tumor DNA (ctDNA) burden. We hypothesized that pre-treatment and early on-treatment ctFE could robustly risk-stratify patients with locally advanced (LA) and oligometastatic non–small cell lung cancer (NSCLC) treated with radiotherapy (RT).Experimental Design:In a prospective phase II clinical trial (NCT03916419), 26 patients with unresectable stage IIB to IIIC NSCLC received magnetic resonance (MR)-guided hypofractionated chemoradiotherapy (chemoRT) followed by immunotherapy. Plasma ctDNA was profiled at baseline and mid-treatment (days 10–14) to derive ctFE and maximum variant allele frequency (Max VAF). A burden-based ctFE threshold derived from baseline samples was applied unchanged to mid-treatment samples and validated in two external cohorts: LA NSCLC treated with chemoRT (LA-RW; n = 94) and oligometastatic NSCLC treated with RT (OM-RW; n = 309).Results:Pre- and mid-treatment ctFE burden strongly stratified overall survival (OS) and progression-free survival (PFS), outperforming Max VAF and ctFE detectability. The baseline ctFE was prognostic for OS (HR 5.93, P = 0.005) and PFS (HR 11.08, P < 0.001) and remained significant at mid-treatment (OS: HR 7.08; PFS: HR 12.06; both P < 0.001). Early ctFE dynamics defined three molecular response groups with OS separation (median OS 60.8 vs. 13.0 vs. 2.9 months; P < 0.001). ctFE remained associated with survival in both validation cohorts.Conclusions:Early ctFE derived from a clinically available, tumor-naïve ctDNA assay enables noninvasive risk stratification in LA and oligometastatic NSCLC treated with RT, supporting its use as a practical biomarker for precision treatment adaptation.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 6: Kaplan-Meier survival analysis of OS and PFS according to baseline nonsynonymous SNV and INDEL detectability in plasma from the LA-WU and LA-RW cohorts. KM survival curves showing (A) OS and (B) PFS based on the presence of SNVs in LA-WU; (C) OS and (D) PFS based on the presence of INDELs in LA-WU; (E) OS based on SNV detectability in LA-RW; and (F) OS based on INDEL detectability in LA-RW. Mutation detectability was defined as the presence of at least one nonsynonymous variant passing assay-level filtering criteria (Methods) at baseline. Hazard ratios from univariate Cox regression analysis and log-rank p-values are shown. HR, hazard ratio; KM, Kaplan-Meier; INDELs, insertions/deletions; LA-RW, locally-advanced real-world NSCLC validation cohort (n = 94); LA-WU, locally advanced NSCLC cohort from Washington University (n = 24); OS, overall survival; PFS, progression-free survival; SNVs, single nucleotide variants.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 6: Kaplan-Meier survival analysis of OS and PFS according to baseline nonsynonymous SNV and INDEL detectability in plasma from the LA-WU and LA-RW cohorts. KM survival curves showing (A) OS and (B) PFS based on the presence of SNVs in LA-WU; (C) OS and (D) PFS based on the presence of INDELs in LA-WU; (E) OS based on SNV detectability in LA-RW; and (F) OS based on INDEL detectability in LA-RW. Mutation detectability was defined as the presence of at least one nonsynonymous variant passing assay-level filtering criteria (Methods) at baseline. Hazard ratios from univariate Cox regression analysis and log-rank p-values are shown. HR, hazard ratio; KM, Kaplan-Meier; INDELs, insertions/deletions; LA-RW, locally-advanced real-world NSCLC validation cohort (n = 94); LA-WU, locally advanced NSCLC cohort from Washington University (n = 24); OS, overall survival; PFS, progression-free survival; SNVs, single nucleotide variants.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 8: Comparison of survival outcomes in each cohort using different ctDNA stratification strategies—either based on ctFE detectability (undetectable: ctFE ≤0.0009, detectable: ctFE >0.0009; Methods) or high and low ctFE based on pre-treatment PFS (low: ctFE ≤0.016411, high: ctFE >0.016411; Methods). Hazard ratios from univariate Cox regression analysis for detectable vs. undetectable ctFE and for high vs. low ctFE are shown as squares; horizontal bars denote 95% CIs. CI, confidence interval; ctDNA, circulating tumor DNA; ctFE, circulating tumor fraction estimate; HR, hazard ratio; LA-RW, locally-advanced real-world NSCLC validation cohort (n = 94); LA-WU, locally-advanced NSCLC Washington University cohort (n = 24 pre-treatment, n = 26 mid-treatment); OM-RW, oligometastatic real-world NSCLC cohort (n = 309); OS, overall survival; PFS, progression-free survival.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Supplementary Figure 8: Comparison of survival outcomes in each cohort using different ctDNA stratification strategies—either based on ctFE detectability (undetectable: ctFE ≤0.0009, detectable: ctFE >0.0009; Methods) or high and low ctFE based on pre-treatment PFS (low: ctFE ≤0.016411, high: ctFE >0.016411; Methods). Hazard ratios from univariate Cox regression analysis for detectable vs. undetectable ctFE and for high vs. low ctFE are shown as squares; horizontal bars denote 95% CIs. CI, confidence interval; ctDNA, circulating tumor DNA; ctFE, circulating tumor fraction estimate; HR, hazard ratio; LA-RW, locally-advanced real-world NSCLC validation cohort (n = 94); LA-WU, locally-advanced NSCLC Washington University cohort (n = 24 pre-treatment, n = 26 mid-treatment); OM-RW, oligometastatic real-world NSCLC cohort (n = 309); OS, overall survival; PFS, progression-free survival.
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Pre-treatment ctDNA variant-level data per patient in the prospective LA-WU cohort.
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Early ctDNA Stratifies Survival in Locally Advanced and Oligometastatic Lung Cancer Treated with Radiotherapy
Pre-treatment ctDNA variant-level data per patient in the prospective LA-WU cohort.